

This is an important document and requires your immediate attention.

If you are in any doubt as to any aspect of the proposals referred to in this document or as to the action you should take, you should consult an independent financial adviser. If you have recently sold or transferred your shares in OKYO Pharma Limited you should forward this document to your bank, stockbroker or other agent through whom the sale or transfer was effected for transmission to the purchaser or transferee.

The registered office of OKYO Pharma Limited is Martello Court, Admiral Park, St Peter Port, Guernsey GY1 3HB. Incorporated and registered in Guernsey No. 65220.



OKYO Pharma Limited

Notice of

Annual General Meeting

7 September 2022 at 12.00 midday

In line with the approach taken by OKYO Pharma Limited ("Company") at the 2021 Annual General Meeting ("AGM"), we are utilising the provisions in our articles of association ("Articles") to convene and hold this year's AGM as a virtual meeting, which is explained in the letter from the chairman of the Company ("Chairman") set out on pages 4 to 5 of this notice.

All voting on the resolutions ("Resolutions") at the AGM will be conducted on a poll, which means that you should submit your proxy as soon as possible. There will be a limited opportunity to submit a separate poll card in a short interval after the AGM formally concludes.

Contents

1. Letter from the Chairman	4 to 5
2. Notice of AGM and Resolutions to be proposed	6 to 8
3. Notes to Resolutions	9 to 12
4. Shareholder notes	12 to 16
5. Contact details	17

Key times and dates

Dispatch of this document	18 August 2022
Latest time for receipt of proxies	12.00 midday on 5 September 2022
AGM	12.00 midday on 7 September 2022

How to vote

Your votes matter. If you cannot attend, please vote your shares by appointing the Chairman of the Company as your proxy. You can vote by returning the form of proxy (the "**Form of Proxy**") that you received with this to exercise all or any of your rights to attend, speak and vote at the AGM.

All voting at the AGM will be held as a poll in accordance with the provisions of our Articles, so you can rest assured that your vote will count. You will be able to submit a poll card (if you wish to change your votes contained in your completed Form of Proxy or have not voted prior to the meeting) in a short window after the meeting has formally closed. Instructions on how to do this will be given on the meeting platform.

A shareholder may appoint one or more proxies to exercise all or any of their rights to attend, speak and vote at AGM, provided that each proxy is appointed to exercise the rights attached to a different ordinary share or ordinary shares held by that shareholder. A proxy need not be a member of the Company. To be valid, the form of proxy provided or other instrument appointing a proxy must be emailed to externalproxyqueries@computershare.co.uk or received by post at the offices of the Company's registrar, Computershare Investor Services (Guernsey) Limited, (the "**Registrar**"), at the address shown on the Form of Proxy.

How to speak

If you wish to raise a question at the AGM, we ask that you submit your question in advance. We would politely remind you that the board of directors ("**Board**" or "**Directors**") will not answer questions relating to the individual rights of shareholders at the AGM itself, but if you wish to submit such a question by email, we will respond to the extent we are able.

If you chose to submit a question, we will confirm to you at least 48 hours in advance of the meeting that the question will be addressed. Unless you specifically request otherwise, the Chairman will put your question to the meeting and identify you by name as the person who has put the question (in the same way as he would ask you to identify yourself at an in-person meeting). Conducting the meeting in this way will allow everyone present to clearly hear the question.

In addition, there will be a short period at the start of the meeting for additional questions, but we would be very grateful if any matters could be raised in advance, as this will enable questions to be dealt with expediently.

Questions on the day will be taken by shareholders using the electronic "raise your hand" feature or typing their question into the Q&A box in the meeting. You will be kept on mute by the meeting host unless and until you are invited to ask your question(s).

Please submit any questions by email to info@okyopharma.com with the subject line "AGM Question".

Letter from the Chairman

Dear Shareholder,

I look forward to welcoming you at the AGM of the Company, on 7 September 2022. The AGM will start at 12.00 midday.

1. Before the AGM

In the usual way we ask and encourage shareholders to vote for the AGM Resolutions by appointing the Chairman as a shareholder's proxy. Accordingly, shareholders are encouraged to cast their proxy by completing the enclosed Form of Proxy and return it by post to Computershare Investor Services (Guernsey) Limited, c/o The Pavilions, Bridgwater Road, Bristol BS99 6ZY, as soon as possible. To be valid, the Form of Proxy provided or other instrument appointing a proxy must be received by 12.00 midday on 5 September 2022, or in the case of shares held through CREST, via the CREST system.

In accordance with the Company's articles of association, all of the voting at the meeting will be conducted on a poll and there will be no show of hands. This means that votes will be counted for all the shares that you have.

Please remember to submit any questions in advance in accordance with the instructions on page 2 by email to info@okyopharma.com with the subject line "AGM Question".

If you wish to appoint a corporate representative, please contact the Registrar in the usual way.

2. On the Day of the Meeting

The meeting takes place at 12.00 midday. on 7 September 2022.

To join the meeting type (or paste) the following web address into your web browser:

<https://mmitc-collab.webex.com/mmitc-collab/j.php?MTID=m6d0e97fb606d3f30d0db2c68b84b6ae5>

You will be asked to enter a password to gain access to the meeting. This code can be found on the bottom section of your Form of Proxy. Please detach and keep this portion of the Form of Proxy before returning the Form of Proxy.

When the meeting opens at the appointed time, you will be able to see and hear the Chairman. The Chairman will open the meeting and address any questions that have been submitted in advance. There will then be a short opportunity to put any additional questions. Shareholders should indicate if they would like to ask a question using the electronic "raise your hand" feature or by typing their question into the Q&A box in the meeting. All attendees will remain muted by the host unless and until they are invited to ask a question.

The Chairman will then formally put the resolutions to the meeting and advise of the proxy votes received in advance.

The meeting will then formally close.

As shareholders exit the meeting, they will have the option to submit an electronic poll card to record their vote.

If you (a) have already submitted a proxy instruction and do not wish to change your vote; or (b) do not wish to vote, you can click on the button to skip this step.

The voting facility will switch off 30 minutes after the close of the meeting.

The results of the meeting will be announced by RNS and posted to the Company's website www.okyopharma.com on the day of the meeting. The full poll results will also be published on this website at the same time.

The business of the AGM comprises Resolutions that public companies regularly bring to shareholders.

The following committees of the Board are currently constituted with membership as set out below:

Audit, Risk and Disclosure committee

Willy Simon
Bernard Denoyer
John Brancaccio (Chair)

Remuneration committee

Willy Simon (Chair)
Bernard Denoyer
John Brancaccio

Nomination committee

Willy Simon
Bernard Denoyer (Chair)
John Brancaccio

In accordance with good corporate governance, all directors of the Company shall retire by rotation. Resolutions are therefore proposed to approve the re-election of Gabriele Cerrone, Bernard Denoyer, Gary Jacob, Willy Simon and John Brancaccio.

Resolutions are also proposed to receive the Company's annual report and accounts for the year ended 31 March 2022 (the "**Annual Report**"), to appoint the Company's auditors and to provide certain customary authorities to the Company's directors. The full text of the Resolutions proposed at the AGM is set out in the formal notice of the AGM starting on page 6 of this document. Explanatory notes on all the Resolutions to be considered at the AGM start on page 9 of this document.

The Board is recommending that Shareholders support all the Resolutions before the AGM by returning your proxy vote to the Registrar, Computershare Investor Services (Guernsey) Limited, c/o The Pavilions, Bridgwater Road, Bristol BS99 6ZY as soon as possible but in any event, so as to reach the aforementioned address by no later than 12.00 midday on 5 September 2022. Full details about how to vote and attend the AGM is given on pages 13 to 16 of this notice.

If you have not elected to receive Shareholder communications electronically, you will receive a proxy card with this notice. However, online voting is quicker and more secure than paper voting and saves OKYO time and resources in processing the votes. If you have not already done so, I urge you to visit the Registrar's investor relations web pages at www-uk.computershare.com/Investor and provide an email address for future communications.

I look forward to hearing from you at the AGM.

Gabriele Cerrone
Non-Executive Chairman
18 August 2022

Notice of AGM and Resolutions to be proposed

Notice is hereby given that the AGM of OKYO Pharma Limited will be held as a remote meeting only on 7 September 2022, commencing at 12.00 midday, for the transaction of the following business.

The Board considers that Resolutions 1 to 10 are in the best interests of the Company and its shareholders as a whole and recommends that you vote in favour of these Resolutions. Resolutions 1 to 9 will be proposed as ordinary resolutions and Resolution 10 will be proposed as a special resolution.

Resolution 1

Ordinary Resolution: Report and accounts

To receive the Company's Annual Report including accounts for the year ended 31 March 2022.

See notes on page 9

Resolution 2

Ordinary Resolution: Directors' remuneration report

To approve the directors' remuneration report contained on page 26 of the Annual Report.

See notes on page 9.

Resolution 3

Ordinary Resolution:

To re-elect Mr Willy Simon as a Director.

See biography on pages 9 to 10.

Resolution 4

Ordinary Resolution:

To re-elect Dr Gary S Jacob as a Director.

See biography on pages 10.

Resolution 5

Ordinary Resolution:

To re-elect Mr John Brancaccio as a Director.

See biography on pages 10 to 11.

Resolution 6

Ordinary Resolution:

To re-elect Mr Gabriele Cerrone as a Director.

See biography on page 11.

Resolution 7

Ordinary Resolution:

To re-elect Mr Bernard Denoyer as a Director.

See biography on page 11.

Resolution 8

Ordinary Resolution: Appointment of auditors and fixing of auditor's remuneration

To appoint Mazars LLP of Tower Bridge House, St Katharine's Way, St Katharine's & Wapping, London E1W 1DD as the Company's auditors from the conclusion of the meeting until the conclusion of the next general meeting before which accounts are laid and to authorise the Directors to fix the auditors' remuneration.

See notes on page 11.

Resolution 9

Ordinary Resolution: Directors' authority to allot shares

That:

- a) In accordance with article 4 of the Company's Articles the Directors be generally and unconditionally authorised to:
- i. allot unissued shares in the Company and to grant rights to subscribe for or to convert any security into shares in the Company:
 - a. up to an aggregate number of 466,963,355 ordinary shares in the Company; and
 - b. comprising equity securities up to an aggregate number of 466,963,355 in connection with an offer by way of a rights issue:
 - I. to holders of ordinary shares in proportion (as nearly as may be practicable) to their existing holdings; and
 - II. to people who are holders of other equity securities if this is required by the rights of those securities or, if the directors consider it necessary, as permitted by the rights of those securities;

and so that the directors may impose any limits or restrictions and make any arrangements which they consider necessary or appropriate to deal with treasury shares, fractional entitlements, record dates, legal, regulatory or practical problems in, or under the laws of, any territory or any other matter, for a period expiring (unless previously renewed, varied or revoked by the Company in general meeting) at the end of the next annual general meeting of the Company after the date on which this Resolution 9 is passed (or, if earlier, at the close of business on 31 December 2023); and
 - ii. make an offer or agreement prior to the expiry of this authority which would or might require unissued shares to be allotted, or rights to subscribe for or convert any security into shares to be granted, after expiry of this authority and the directors may allot unissued shares and grant rights in pursuance of that offer or agreement as if this authority had not expired;
- b) subject to paragraph (c), all existing authorities to allot unissued shares in the Company (and/or to grant rights to subscribe for or to convert any security into shares in the Company) given to the directors otherwise than pursuant to these Resolutions be revoked by this Resolution 9; and
- c) paragraph (b) shall be without prejudice to the continuing authority of the directors to allot unissued shares, or grant rights to subscribe for or convert any security into shares, pursuant to an offer or agreement made by the Company before the expiry of the authority pursuant to which such offer or agreement was made.

See notes on pages 11 to 12.

Resolution 10

Special resolution: authority for disapplication of pre-emption rights

That, subject to the passing of Resolution 9, the directors be generally empowered, pursuant to the Articles to allot shares in the Company for cash, pursuant to the authority conferred by Resolution 9 as if there were no restrictions on the Company's ability to allot shares. This power:

- a) expires (unless previously renewed, varied or revoked by the Company in general meeting) at the end of the next annual general meeting of the Company after the date on which this Resolution 10 is passed (or, if earlier, at the close of business on 31 December 2023), but the Company may make an offer or agreement which would or might require equity securities to be allotted after expiry of this power and the directors may allot equity securities in pursuance of that offer or agreement as if this power had not expired;

- b) subject to paragraph (c) of this Resolution 10, shall be limited to the allotment of equity securities in connection with an offer of equity securities (but in the case of the authority granted under Resolution 9(a)(i)(b), by way of a rights issue only):
 - i. to the ordinary shareholders in proportion (as nearly as may be practicable) to their existing shareholdings; and
 - ii. to people who hold other equity securities, if this is required by the rights of those securities or, if the directors consider it necessary, as permitted by the rights of those securities, and so that the directors may impose any limits or restrictions and make any arrangements which they consider necessary or appropriate to deal with treasury shares, fractional entitlements, record dates, legal, regulatory or practical problems in, or under the laws of, any territory or any other matter;
- c) in the case of the authority granted under Resolution 9(a)(i)(a) shall be limited to the allotment of equity securities for cash otherwise than pursuant to paragraph (b) of this Resolution 10 up to an aggregate number of 466,963,355 ordinary shares in the Company; and
- d) shall apply, in relation to a sale of shares in the Company which is an allotment of equity securities by virtue of the Articles, as if in the first paragraph of this Resolution 10 the words “pursuant to the authority conferred by Resolution 9” were omitted.

See notes on page 12.

By order of the Board.

Orrick, Herrington & Sutcliffe (UK) LLP

Company Secretary

18 August 2022

Notes to Resolutions

Resolutions 1 to 9 are proposed as ordinary resolutions. This means that for each of those Resolutions to be passed, more than half of the votes cast by persons entitled to vote must be in favour of such Resolution. Resolution 10 is proposed as a special resolution. This means that for Resolution 10 to be passed, at least three quarters of the votes cast by persons entitled to vote must be in favour of such Resolution.

Notes to Resolution 1

Reports and accounts

The Board will present Annual Report for the year ended 31 March 2022 to shareholders at the AGM. The report of the directors, the accounts and the report of the Company's auditors on the accounts are contained within the Annual Report, which can be found on the Company's website at www.okyopharma.com.

Notes to Resolution 2

Directors' Remuneration Report

The directors' remuneration report, which can be found on page 28 of the Annual Report gives details of the directors' remuneration for the period commencing on 1 April 2021 and ended on 31 March 2022. The report includes a statement from the Chairman of the Remuneration Committee, the components of the executive directors' remuneration and the non-executive directors' fees.

The Company's auditors, Mazars LLP, have audited those parts of the directors' remuneration report which are required to be audited and their report may be found in the Annual Report. The Annual Report has been approved by the Board and signed on its behalf by the Chairman of the Remuneration Committee.

The vote on the directors' remuneration report is advisory in nature and therefore not binding on the Company.

Notes to Resolutions 3 to 7 (inclusive)

Re-election of directors

It is in accordance with good corporate governance that all directors of the Company retire and offer themselves for re-election at each annual general meeting. Accordingly, all five of the existing directors will be standing for re-election at the AGM.

Resolution 3 – reappointment of Mr Willy Simon as a director

Mr. Simon is retiring from his role as a director of the Company and offers himself for reappointment.

Willy Jules Simon is a banker and worked at Kredietbank N.V. and Citibank London before serving as an executive member of the Board of Generale Bank NL from 1997 to 1999 and as the chief executive of Fortis Investment Management from 1999 to 2002. He acted as chairman of Bank Oyens & van Eeghen from 2002 to 2004. He was chairman of AIM-traded Velox3 plc (formerly 24/7 Gaming Group Holdings plc) until 2014 and had been a director of Playlogic Entertainment Inc., a Nasdaq OTC listed company. Mr. Simon has been the chairman of Bever Holdings, a company listed in Amsterdam, since 2006 and Chairman of Ducat Maritime since 2015. He is also a non-executive director of Tiziana Life Sciences plc and Accustem Sciences Limited.

Mr. Simon chairs the Remuneration Committee of the Board (which also comprises John Brancaccio and Bernard Denoyer) and sits as a member of Audit, Risk and Disclosure Committee of the Board (which also comprises John Brancaccio as chair and Bernard Denoyer)

and the Nomination Committee of the Board (which also comprises John Brancaccio and Bernard Denoyer as Chair).

Resolution 4 – reappointment of Dr Gary S Jacob as a director

Dr. Jacob is retiring from his role as a director of the Company and offers himself for reappointment.

Gary S. Jacob, Ph.D. has over 35 years of extensive experience in the pharmaceutical and biotechnology industries across multiple disciplines, including research and development, operations, business development, capital financing activities and senior management expertise. He has developed broad and influential contacts throughout the biopharmaceutical, financial, banking and investor communities. Dr. Jacob is the Co-Founder and former CEO of Synergy Pharmaceuticals, Inc, a biopharmaceutical company, where he held various positions from July 2008 to November 2018 and served as its Chairman from September 2013 to November 2018. On 12 December 2018, Synergy Pharmaceuticals Inc. filed a petition for relief under Chapter 11 of the U.S. Bankruptcy Code. He is the co-inventor of the FDA-approved drug Trulance® which is currently marketed in the U.S. by Bausch Health, Inc. to treat functional GI disorders. Dr. Jacob is also the former CEO and Managing Director of Immuron, Inc., an Australian biotechnology company dual-listed on the Australian ASX exchange and on Nasdaq. Dr. Jacob currently is Chairman of the Board of Hepion Pharmaceuticals, Inc., a public Nasdaq-listed company with a drug in clinical development to treat non-alcoholic steatohepatitis (NASH) and is also on the Board of Directors of Rasna Therapeutics, Inc. He served as Chief Executive Officer and Director of Callisto Pharmaceuticals, Inc. from May 2003 until January 2013.

Prior to his involvement with Callisto and Synergy, Dr. Jacob was at Monsanto/G.D. Searle, where he was Director of Glycobiology and a Monsanto Science Fellow, specializing in the field of Glycobiology and drug discovery. Dr. Jacob holds over 30 patents and is the co-inventor of two pharmaceutical drugs which are FDA approved. Dr. Jacob earned a B.S. cum laude in Chemistry from the University of Missouri – St. Louis and holds a Ph.D. in Biochemistry from the University of Wisconsin-Madison.

Resolution 5 – reappointment of Mr John Brancaccio as a director

Mr Brancaccio is retiring from his role as a director of the Company and offers himself for reappointment.

Mr. Brancaccio, retired Certified Public Accountant, is a financial executive with extensive international and domestic experience in pharmaceutical and biotechnology for privately and publicly held companies. From 2000 to 2002, Mr. Brancaccio was the Chief Financial Officer/Chief Operating Officer of Eline Group, an entertainment and media company. From May 2002 until March 2004, Mr. Brancaccio was the Chief Financial Officer of Memory Pharmaceuticals Corp., a biotechnology company. From April 2004 until May 2017, Mr. Brancaccio was the Chief Financial Officer of Accelerated Technologies, Inc., an incubator for medical device companies. Mr. Brancaccio is currently a director of Cardiff Oncology, Inc., Rasna Therapeutics, Inc., Tiziana Life Sciences plc and Hepion Pharmaceuticals, Inc.

Mr. Brancaccio chairs the Audit and Risk Committee of the Board (which also comprises Willy Simon and Bernard Denoyer) and sits as a member of the Remuneration Committee and Nomination Committee of the Board.

Resolution 6 – reappointment of Mr Gabriele Cerrone as a director

Mr. Cerrone is retiring from his role as a director of the Company and offers himself for reappointment.

Gabriele Cerrone has a successful track record and extensive experience in the financing and restructuring of micro-cap biotechnology companies. He has founded nine biotechnology companies in oncology, infectious diseases and molecular diagnostics, and has taken six of these companies to Nasdaq and one to the AIM Market in London. Mr. Cerrone co-founded

Trovagene, Inc. (Nasdaq: TROV), a molecular diagnostic company and served as its Co-Chairman; he was a co-founder and served as Chairman of both Synergy Pharmaceuticals, Inc. (Nasdaq: SGYP) and Callisto Pharmaceuticals, Inc. (OTCMKTS: CLSP), and was a Director of and led the restructuring of Siga Technologies, Inc. (Nasdaq: SIGA). Mr. Cerrone also co-founded FermaVir Pharmaceuticals, Inc. and served as Chairman of the Board until its merger in September 2007 with Inhibitex, Inc. Mr. Cerrone served as a director of Inhibitex, Inc. until its US\$2.5bn sale to Bristol Myers Squibb Co in 2012.

Mr. Cerrone is the Executive Chairman and Co-Founder of Gensignia Life Sciences, Inc., a molecular diagnostics company focused on oncology using microRNA technology; Executive Chairman and Founder of Tiziana Life Sciences plc (AIM: TILS) an oncology focused therapeutics company; Executive Chairman of Accustem Sciences Limited, a genomics-based personalised medicine business focussed on breast cancer patients; Chairman and Co-Founder of Rasna Therapeutics Limited, a company focused on the development of therapeutics for leukaemias; Co-Founder of ContraVir Pharmaceuticals, Inc. (Nasdaq: CTRV); and founder of BioVitas Capital Ltd.

Resolution 7 – reappointment of Mr Bernard Denoyer as a director

Mr. Denoyer is retiring from his role as a director of the Company and offers himself for reappointment.

Bernard F. Denoyer has 49 years of financial management experience including his service as Senior Vice President, Finance and Secretary of development stage Synergy Pharmaceuticals, Inc, from July 2008 until FDA approval and his retirement in June 2017. Between 2004 and January 2013 Mr. Denoyer concurrently served as Principal Financial Officer of Synergy's former parent company, Callisto Pharmaceuticals, Inc. From October 2000 to December 2003, Mr. Denoyer was an independent consultant. Prior to this, Mr. Denoyer served as Chief Financial Officer and Senior Vice President of META Group, Inc.

Mr. Denoyer earned his CPA with Ernst & Young in 1975. He received a Masters Certificate of Accounting from the Kellogg Graduate School of Management in 1974, an MBA in Finance with honours from Columbia Business School in 1972 and a BA in Economics from Fairfield University in 1969. Mr. Denoyer is fluent in French and studied in Paris at l'Istitut d'Etude Politique et Economique in 1968. He is currently serving on the Board of Trustees for two not-for-profits, St. Edmunds Retreat, Inc. and Midwestern Connecticut Council on Alcoholism, Inc.

Mr. Denoyer chairs the Nomination Committee of the Board (which also comprises Willy Simon and John Brancaccio) and sits as a member of the Remuneration Committee and Nomination Committee of the Board.

Notes to Resolution 8

Appointment of auditor

At each general meeting at which the accounts are laid before the members, the Company is required to appoint an auditor to serve until the next such meeting. Resolution 9 proposes the appointment of Mazars LLP, until the conclusion of the next general meeting of the Company at which accounts are laid.

Notes to Resolution 9

Directors' authority to allot shares

Resolution 9 seeks shareholder approval to authorise the directors to allot unissued shares in the Company or grant rights to subscribe for, or convert any security into, shares in the Company up to:

- a) an aggregate number of 466,963,355 ordinary shares (representing approximately one-third of the Company's issued ordinary share capital as at close of business on 18 August 2022 (being the latest practicable date prior to publication of this Notice)); and
- b) an aggregate number of a further 466,963,355 ordinary shares (including within such limit any shares issued or rights granted under paragraph (a) above) in connection with a pre-emptive offer to existing shareholders by way of a rights issue.

This authority would expire at the conclusion of the next annual general meeting of the Company or, if earlier, the close of business on 31 December 2023. The extent of these authorities are in accordance with applicable institutional guidelines. The Board is likely to exercise this authority, at least in part, in the coming months to fund Phase II clinical trials.

Notes to Resolution 10

Disapplication of pre-emption rights

Subject to certain exceptions, before the directors may allot equity securities wholly for cash, they must first offer them to existing shareholders in proportion to their holdings of ordinary shares. Resolution 10 would empower the directors to allot equity securities wholly for cash as if such pre-emption rights did not apply:

- a) in connection with a rights issue up to the aggregate number authorised pursuant to Resolution 9; and
- b) otherwise than in connection with a rights issue, up to an aggregate number of 466,963,355 ordinary shares, which represents approximately 30% of the Company's issued ordinary share capital as at close of business on 18 August 2022.

This authority would expire at the conclusion of the next annual general meeting of the Company or, if earlier, the close of business on 31 December 2023. The extent of this authority is in accordance with applicable institutional guidelines. The Board is likely to exercise this authority, at least in part, in the coming months to fund Phase II clinical trials.

Shareholder notes

Voting

When is my voting entitlement fixed?

To attend, speak and vote at the meeting you must be a registered holder of shares at 6.00 p.m. on 6 September 2022. Your voting entitlement will depend on the number of shares you hold at that time.

I can't attend the remote meeting but want to vote – what can I do?

If you are a registered holder and cannot attend, you can appoint the Chair or any other person to attend, speak and vote on your behalf. This person is called your proxy. Your proxy does not have to be a Shareholder.

You can instruct your proxy how to vote. Where no specific instruction is given, your proxy may vote at his or her discretion or refrain from voting, as he or she sees fit.

You can appoint more than one proxy in relation to different shares within your holding.

You can appoint a proxy and submit voting instructions:

- Via CREST (see note opposite).
- If you have received a hard-copy proxy form, by completing and returning the paper proxy card. Please read the instructions carefully to ensure you have completed and signed the card correctly. Any alterations must be initialled.

Proxies not properly notified to the Registrar may be denied access to the meeting.

If you own shares jointly, any one Shareholder may sign the proxy card. If more than one joint holder submits a card, the instruction given by the first listed on the Shareholder register will prevail.

The AGM will commence at 12.00 midday on 7 September 2022. The AGM will be an exclusively electronic meeting and will be conducted in accordance with the Company's Articles

By when do I have to submit my vote?

Proxy appointments and voting instructions, including any amendments, must be received by the Registrar by 12.00 midday on 5 September

2022. If you miss this deadline and wish to submit a new vote or amend an existing vote, you can only do so by attending the meeting in person and voting.

I already voted but have changed my mind – can I change my vote?

You can submit a new instruction online at any time before the time and date above. If you wish to amend a paper instruction you must do so in writing and sign your new instruction.

The voting instruction received last will be the one that is followed. If a postal instruction and an online instruction are received on the same day, the online instruction will be followed.

I hold shares on behalf of several others – can I vote part of the holding separately?

You can appoint more than one proxy using the paper proxy form provided it is in relation to different shares.

Corporate Shareholders may either appoint one or more proxies, or alternatively appoint one or more corporate representatives in relation to different shares, using the paper proxy form or via CREST.

Multiple proxies and corporate representatives may all attend and speak at the meeting and may vote the shares that their respective appointments represent in different ways.

I am a CREST member – can I use the CREST system to vote?

CREST members who wish to appoint a proxy or proxies through the CREST electronic proxy appointment service may do so for the AGM and any adjournment by using the procedures described in the CREST manual (www.euroclear.com/crest). CREST personal members or other CREST-sponsored members and those CREST members who have appointed a voting service provider should refer to their CREST sponsor or voting service provider, who will be able to take the appropriate action on their behalf.

In order for a proxy appointment or instruction made using the CREST service to be valid, the appropriate CREST message (a CREST proxy instruction) must be properly authenticated in accordance with Euroclear's specifications and must contain the information required for such instructions, as described in the CREST manual.

All messages relating to the appointment of a proxy or an instruction to a previously appointed proxy must be transmitted so as to be received by the Registrar (3RA50) by 12.00 midday on 5 September 2022. It is the responsibility of the CREST member concerned to take such action as shall be necessary to ensure that a message is transmitted by means of the CREST system by any particular time. In this connection, CREST members and, where applicable, their CREST sponsors or voting service providers, are referred, in particular, to those sections of the CREST manual concerning practical limitations of the CREST system and timings. The Company may treat a CREST proxy instruction as invalid in the circumstances set out in Regulation 35(5)(a) of the Uncertificated Securities Regulations 2001.

I have a power of attorney from a Shareholder – how can I vote?

You can vote using the paper proxy card only. You must ensure that the power of attorney and the proxy card have been deposited with the Registrar by 12.00 midday on 5 September 2022.

The Meeting

Where and when will the meeting be held?

The meeting will be held exclusively as an electronic meeting on 7 September 2022.

The meeting will start at 12.00 midday so please allow plenty of time to log into the meeting. The meeting will be available for login at

<https://mmitc-collab.webex.com/mmitc-collab/j.php?MTID=m6d0e97fb606d3f30d0db2c68b84b6ae5>

Is the meeting at the same location as last year?

The meeting will be held as a remote meeting only, in accordance with the Company's Articles.

I want to participate in the meeting but cannot attend – what can I do?

You can vote your shares by appointing a proxy – see notes on page 13. Any voting instructions you have validly given in advance will be counted at the meeting.

What documents do I need to bring?

To log into the remote meeting, you need to type or paste the following web address into your web browser:

<https://mmitc-collab.webex.com/mmitc-collab/j.php?MTID=m6d0e97fb606d3f30d0db2c68b84b6ae5>

You will be asked to enter a password to gain access to the meeting. This can be found on the bottom section of your proxy form or, if you have elected to receive electronic communications from the Company, in an email to be sent to you on the morning of the AGM. A separate email with the meeting link embedded in it will also be sent. Please check your spam folder or filter if you do not receive these emails.

I hold shares through a broker or nominee, how can I attend?

You will need to ask your broker or nominee to appoint you as either a proxy or as a corporate representative. If they appoint you as a proxy, the appointment must be notified to the Registrar by the appropriate deadline (see notes on pages

13 to 14). If they appoint you as a corporate representative, they will need to write a letter to us setting out the details of the appointment and of your shareholding, and you will need to bring the letter with you to the meeting along with photographic proof of identity. If you do not have such a letter, or the Registrar has not been notified of your appointment as a proxy, you will be denied entry to the meeting.

May I bring a guest?

The AGM is a private meeting of Shareholders and their representatives. Guests are not entitled to attend the meeting as of right, but they may be permitted entry at the absolute discretion of the Company at all times. You must contact us in advance if you would like to bring a guest: info@okyopharma.com.

Proxies, corporate representatives and employee share plan participants may not bring guests to the meeting.

May I ask a question at the meeting?

The Chair will announce when you will have an opportunity to ask questions. If you wish to ask a question, please use the electronic "raise your hand" facility or type your question into the Q&A box in the meeting. You will be kept on mute by the meeting host unless and until you are invited to speak.

Please endeavour to keep your questions short.

How can I vote at the meeting?

As shareholders exit the remote meeting, they will have the option to submit an electronic poll card to record their vote. If you (a) have already submitted a proxy instruction and do not wish to change your vote, or (b) do not wish to vote, you can click on the button to skip this step.

The voting facility will close 30 minutes after the meeting ends.

How are the votes counted?

Voting on all substantive Resolutions is by a poll. In a Company such as ours, we think poll voting is the fairest approach. There will be no voting on the substantive Resolutions by a show of hands.

We have included a 'vote withheld' column on our proxy and poll cards. A vote withheld is not a vote

in law and will not be counted in calculation of the proportion of votes 'for' or 'against' a Resolution.

How can I find out the result of the vote?

It is expected that the total of the votes cast by Shareholders 'for' or 'against' or 'withheld' on each Resolution will be published on www.okyopharma.com by 5.00pm on 7 September 2022.

Total voting rights and share capital

As at 17 August 2022 (the latest practicable date before the publication of this notice) the issued share capital of OKYO Pharma Limited comprised 1,415,040,468 Ordinary Shares (excluding treasury shares) of no par value, each with one vote.

The total number of voting rights in OKYO Pharma Limited is 1,415,040,468.

Updates to this number are released via the Regulatory News Service on the last day of each month and can be viewed online at www.okyopharma.com/news.

Contact details

OKYO Pharma Limited

Martello Court
Admiral Park
St Peter Port
Guernsey GY1 3HB
Tel: +44 (0) 207 495 2379
www.okyopharma.com

Solicitors

Orrick, Herrington & Sutcliffe (UK) LLP
107 Cheapside
London EC2V 6DN

The Registrar

Computershare Investor Services (Guernsey)
Limited
c/o The Pavilions
Bridgwater Road
Bristol BS99 6ZY

If you are an Ordinary Shareholder, please contact Computershare Investor Services (Guernsey) Limited at c/o The Pavilions, Bridgwater Road, Bristol BS99 6ZY if you would like to change your election on how you receive Shareholder documents in the future.